A phase I study of bortezomib and temozolomide in patients with advanced solid tumors

PURPOSE: The primary objective was to determine the maximum tolerated doses (MTDs) of the combination of bortezomib and temozolomide in patients with solid tumors. The secondary objective was to evaluate the pharmacokinetics (PK) of bortezomib with and without concurrent hepatic enzyme-inducing anti...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Portnow, J., Frankel, P., Koehler, S., Twardowski, P., Shibata, S., Martel, C., Morgan, R., Cristea, M., Chow, W., Lim, D., Chung, V., Reckamp, K., Leong, L., Synold, T. W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3506384/
https://ncbi.nlm.nih.gov/pubmed/21850464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-011-1721-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky